Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Reply to H. Kantarjian et al.

Steensma DP, Sekeres MA.

J Clin Oncol. 2013 May 10;31(14):1796. No abstract available.

PMID:
23802242
2.

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

Kantarjian H, Wilson W, Ravandi F, Estey E.

J Clin Oncol. 2013 May 10;31(14):1795-6. doi: 10.1200/JCO.2012.48.1465. Epub 2013 Apr 1. No abstract available.

PMID:
23547076
3.

Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.

Sekeres MA, Steensma DP.

J Clin Oncol. 2012 Nov 20;30(33):4061-3. doi: 10.1200/JCO.2012.44.2962. Epub 2012 Sep 24. No abstract available.

PMID:
23008302
4.

Concise drug review: azacitidine and decitabine.

Derissen EJ, Beijnen JH, Schellens JH.

Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13. No abstract available.

5.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.

Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F.

Leukemia. 2012 Nov;26(11):2428-31. doi: 10.1038/leu.2012.153. Epub 2012 Jun 5. No abstract available.

6.

Evidence for a role of decitabine in the treatment of myeloid sarcoma.

Gornicec M, Wölfler A, Stanzel S, Sill H, Zebisch A.

Ann Hematol. 2017 Mar;96(3):505-506. doi: 10.1007/s00277-016-2870-0. Epub 2016 Nov 6. No abstract available.

PMID:
27817041
7.

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G.

Leukemia. 2012 May;26(5):1106-7. doi: 10.1038/leu.2011.342. Epub 2011 Nov 29. No abstract available.

8.

Decitabine studies in chronic and acute myelogenous leukemia.

Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M.

Leukemia. 1997 Mar;11 Suppl 1:S35-6. No abstract available.

PMID:
9130691
9.

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.

Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H.

Am J Hematol. 2015 Jul;90(7):E139-41. doi: 10.1002/ajh.24036. Epub 2015 May 28. No abstract available.

10.

[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].

Gao S, Hu XH, Qiu HY, Xu Y, Jin ZM, He GS, Tang XW, Han Y, Chen SN, Sun AN, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019. Chinese. No abstract available.

PMID:
23827117
11.

MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.

Milne TA.

Haematologica. 2014 Sep;99(9):1405-7. doi: 10.3324/haematol.2014.113357. No abstract available.

12.

First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.

Schroeder T, Kobbe G.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1703-4. doi: 10.1016/j.bbmt.2015.08.012. Epub 2015 Aug 12. No abstract available.

13.

Azacitidine in AML: a treatment option?

Huls G.

Blood. 2015 Jul 16;126(3):283-4. doi: 10.1182/blood-2015-06-648071.

14.

The role of hypomethylating agents in the treatment of elderly patients with AML.

Al-Ali HK, Jaekel N, Niederwieser D.

J Geriatr Oncol. 2014 Jan;5(1):89-105. doi: 10.1016/j.jgo.2013.08.004. Epub 2013 Sep 24. Review.

15.

Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.

Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G.

Bone Marrow Transplant. 2012 Jul;47(7):1008-9. doi: 10.1038/bmt.2011.210. Epub 2011 Nov 14. No abstract available.

PMID:
22080965
16.

A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy.

O'Reilly MA, McHale C, Almazmi A, Hameed A, Benjamin D, O'Connell N, Murphy P, Quinn J, Thornton P, O'Gorman P, Frankova H, Sargent J, Verburgh E, McHugh J, Evans P, Enright H.

Leuk Lymphoma. 2014 Dec;55(12):2950-1. doi: 10.3109/10428194.2014.904512. Epub 2014 Apr 22. No abstract available.

PMID:
24628297
17.

Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.

Yamamoto R, Yokoyama A, Yoneda M, Ohashi K, Hosoda T, Kagoo T, Boku S, Ueno H, Yano T.

Ann Hematol. 2014 Dec;93(12):2081-2. doi: 10.1007/s00277-014-2119-8. Epub 2014 May 27. No abstract available.

PMID:
24863693
18.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
19.

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6. No abstract available.

PMID:
26541345
20.

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.

Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. No abstract available.

Supplemental Content

Support Center